Cargando…

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

BACKGROUND: A growing body of evidence supports the role of platelets in cancer metastasis, escape from immune surveillance, and angiogenesis. Mean platelet volume (MPV), which reflects platelet turnover, is reported routinely as part of automated complete blood count. Accumulating evidence suggests...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Kousuke, Yasumoto, Atsushi, Amano, Yosuke, Kage, Hidenori, Goto, Yasushi, Yatomi, Yutaka, Takai, Daiya, Nagase, Takahide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128600/ https://www.ncbi.nlm.nih.gov/pubmed/30192878 http://dx.doi.org/10.1371/journal.pone.0203625

Ejemplares similares

Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma
por: Hiyama, Noriko, et al.
Publicado: (2018)

Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma
por: Maemura, Keita, et al.
Publicado: (2018)

High expression of IRE1 in lung adenocarcinoma is associated with a lower rate of recurrence
por: Sakatani, Toshio, et al.
Publicado: (2017)

The chimeric transcript RUNX1–GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer
por: Ishikawa, Rie, et al.
Publicado: (2016)

Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML
por: Watanabe, Kousuke, et al.
Publicado: (2020)

Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer
por: Watanabe, Kousuke, et al.
Publicado: (2015)

NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer
por: Yotsumoto, Takuma, et al.
Publicado: (2020)

Integrin α11 in non–small cell lung cancer is associated with tumor progression and postoperative recurrence
por: Ando, Takahiro, et al.
Publicado: (2019)

Cerebral Arterial Air Embolism after Diagnostic Flexible Fiberoptic Bronchoscopy: A Case Report and Review of the Literature
por: Maemura, Keita, et al.
Publicado: (2018)

Alternative polyadenylation is associated with lower expression of PABPN1 and poor prognosis in non-small cell lung cancer
por: Ichinose, Junji, et al.
Publicado: (2014)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report
por: Amano, Yosuke, et al.
Publicado: (2022)

Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors
por: Zhu, Qi-Qi, et al.
Publicado: (2018)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Development of Pulmonary Artery Aneurysms Due to Behçet's Disease and Resolution after Treatment
por: Kage, Hidenori, et al.
Publicado: (2016)

Acute Arterial Thrombosis during Postoperative Adjuvant Cisplatin-based Chemotherapy for Completely Resected Lung Adenocarcinoma
por: Sato, Chihiro, et al.
Publicado: (2017)

Successful Treatment of Mediastinal Unicentric Castleman's Disease Using Video-Assisted Thoracoscopic Surgery with Preoperative Embolization
por: Amano, Yosuke, et al.
Publicado: (2013)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Multiple cerebral infarctions in ROS1‐rearranged lung adenocarcinoma
por: Ikushima, Hiroaki, et al.
Publicado: (2021)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
por: Shi, Xuefei, et al.
Publicado: (2020)

Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing
por: Kage, Hidenori, et al.
Publicado: (2019)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
por: Ando, Toshinori, et al.
Publicado: (2021)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
por: Duggirala, Krishna Babu, et al.
Publicado: (2022)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

Diagnostic prediction of COVID-19 based on clinical and radiological findings in a relatively low COVID-19 prevalence area
por: Amano, Yosuke, et al.
Publicado: (2021)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_m9p3b31c6u4ld06v33tp31834e